Cathepsin B inhibition for Alzheimer's disease treatment
Columbia University's research explores Cathepsin B inhibition as a strategy to reduce amyloid-beta plaque formation in Alzheimer's disease, potentially improving cognitive function. This approach targets a key process in neurodegeneration with low risk of adverse effects.
Overview
Columbia University is investigating the inhibition of Cathepsin B (CatB) as a therapeutic strategy for Alzheimer's disease (AD). CatB is involved in the processing of amyloid-beta precursor protein (APP), a critical step in the formation of amyloid-beta plaques. By inhibiting CatB, this research aims to reduce plaque formation and mitigate cognitive decline in AD. The approach is based on knockout studies that show reduced amyloid-beta burden and improved cognitive outcomes without significant adverse effects, presenting a novel and promising avenue for halting AD progression.
Technical specifications
The research employs several validation methods to assess the efficacy of CatB inhibition:
- Cell-Free Assays: Quantify CatB enzymatic activity and test the specificity and potency of proprietary inhibitors.
- Cell-Based Assays: Evaluate the effect of CatB inhibition on APP processing and amyloid-beta production using neuronal cell culture models.
- Animal Model Validation: Conduct studies in transgenic Alzheimer's mouse models to assess the impact on plaque formation, neuroinflammation, and cognitive function.
These methods aim to validate CatB as a therapeutic target and test the efficacy and pharmacokinetics of sponsor-provided inhibitors in vivo.
Technology readiness level
The research is currently at Technology Readiness Level 2, focusing on the proof of concept phase through laboratory studies and early validation efforts.
About Columbia University
Columbia University is a comprehensive private research university in New York City, combining an Ivy League academic profile with globally engaged scholarship and professional education. Its integration with a major hospital system through Columbia University Irving Medical Center and NewYork-Presbyterian enables clinical collaboration, access to diverse patient populations, and regulated studies at scale. State-of-the-art laboratories and shared core facilities across the Morningside and Manhattanville campuses support co-located industry projects, while proximity to New York’s finance, media, and healthcare ecosystems streamlines talent pipelines and pilot deployments. Industry engages via sponsored research, affiliate programs, executive education, and convenings that connect faculty expertise with corporate R&D priorities. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DoD, alongside New York State and philanthropic sources. Columbia Technology Ventures provides IP management, licensing, startup support, and translational funding mechanisms that lower barriers to commercialization.
delivered to your inbox.